BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 26459098)

  • 1. Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer.
    Alsubhi N; Middleton F; Abdel-Fatah TM; Stephens P; Doherty R; Arora A; Moseley PM; Chan SY; Aleskandarany MA; Green AR; Rakha EA; Ellis IO; Martin SG; Curtin NJ; Madhusudan S
    Mol Oncol; 2016 Feb; 10(2):213-23. PubMed ID: 26459098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
    Massey AJ
    Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response.
    Al-Kaabi MM; Alshareeda AT; Jerjees DA; Muftah AA; Green AR; Alsubhi NH; Nolan CC; Chan S; Cornford E; Madhusudan S; Ellis IO; Rakha EA
    Br J Cancer; 2015 Mar; 112(5):901-11. PubMed ID: 25688741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.
    Middleton FK; Patterson MJ; Elstob CJ; Fordham S; Herriott A; Wade MA; McCormick A; Edmondson R; May FE; Allan JM; Pollard JR; Curtin NJ
    Oncotarget; 2015 Oct; 6(32):32396-409. PubMed ID: 26486089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decarbamoyl mitomycin C (DMC) activates p53-independent ataxia telangiectasia and rad3 related protein (ATR) chromatin eviction.
    Xiao G; Kue P; Bhosle R; Bargonetti J
    Cell Cycle; 2015; 14(5):744-54. PubMed ID: 25565400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ATM and Rad3-Related (ATR) Protein Kinase Pathway Is Activated by Herpes Simplex Virus 1 and Required for Efficient Viral Replication.
    Edwards TG; Bloom DC; Fisher C
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29263259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ZEB1 inhibition sensitizes cells to the ATR inhibitor VE-821 by abrogating epithelial-mesenchymal transition and enhancing DNA damage.
    Song N; Jing W; Li C; Bai M; Cheng Y; Li H; Hou K; Li Y; Wang K; Li Z; Liu Y; Qu X; Che X
    Cell Cycle; 2018; 17(5):595-604. PubMed ID: 29157079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Marek's Disease Virus Disables the ATR-Chk1 Pathway by Activating STAT3.
    Lian X; Bao C; Li X; Zhang X; Chen H; Jung YS; Qian Y
    J Virol; 2019 May; 93(9):. PubMed ID: 30787154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.
    Bryant C; Rawlinson R; Massey AJ
    BMC Cancer; 2014 Aug; 14():570. PubMed ID: 25104095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hsp90 inhibitor-mediated disruption of chaperone association of ATR with hsp90 sensitizes cancer cells to DNA damage.
    Ha K; Fiskus W; Rao R; Balusu R; Venkannagari S; Nalabothula NR; Bhalla KN
    Mol Cancer Ther; 2011 Jul; 10(7):1194-206. PubMed ID: 21566061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATR mediates cisplatin resistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation.
    Gomes LR; Rocha CRR; Martins DJ; Fiore APZP; Kinker GS; Bruni-Cardoso A; Menck CFM
    Cell Death Dis; 2019 Jun; 10(6):459. PubMed ID: 31189884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Chk1 with the small molecule inhibitor V158411 induces DNA damage and cell death in an unperturbed S-phase.
    Wayne J; Brooks T; Massey AJ
    Oncotarget; 2016 Dec; 7(51):85033-85048. PubMed ID: 27829224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aurora-A controls cancer cell radio- and chemoresistance via ATM/Chk2-mediated DNA repair networks.
    Sun H; Wang Y; Wang Z; Meng J; Qi Z; Yang G
    Biochim Biophys Acta; 2014 May; 1843(5):934-44. PubMed ID: 24480460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological significance of ATM-Chk2 expression in sporadic breast cancers: a comprehensive analysis in large cohorts.
    Abdel-Fatah TM; Arora A; Alsubhi N; Agarwal D; Moseley PM; Perry C; Doherty R; Chan SY; Green AR; Rakha E; Ball G; Ellis IO; Madhusudan S
    Neoplasia; 2014 Nov; 16(11):982-91. PubMed ID: 25425972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultrasound activates ataxia telangiectasia mutated- and rad3-related (ATR)-checkpoint kinase 1 (Chk1) pathway in human leukemia Jurkat cells.
    Furusawa Y; Iizumi T; Fujiwara Y; Hassan MA; Tabuchi Y; Nomura T; Kondo T
    Ultrason Sonochem; 2012 Nov; 19(6):1246-51. PubMed ID: 22571845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperoxia activates the ATR-Chk1 pathway and phosphorylates p53 at multiple sites.
    Das KC; Dashnamoorthy R
    Am J Physiol Lung Cell Mol Physiol; 2004 Jan; 286(1):L87-97. PubMed ID: 12959929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there a role for base excision repair in estrogen/estrogen receptor-driven breast cancers?
    Abdel-Fatah TM; Perry C; Arora A; Thompson N; Doherty R; Moseley PM; Green AR; Chan SY; Ellis IO; Madhusudan S
    Antioxid Redox Signal; 2014 Dec; 21(16):2262-8. PubMed ID: 25111287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radio-sensitizing effects of VE-821 and beyond: Distinct phosphoproteomic and metabolomic changes after ATR inhibition in irradiated MOLT-4 cells.
    Šalovská B; Janečková H; Fabrik I; Karlíková R; Čecháková L; Ondrej M; Link M; Friedecký D; Tichý A
    PLoS One; 2018; 13(7):e0199349. PubMed ID: 30001349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chk1 is dispensable for G2 arrest in response to sustained DNA damage when the ATM/p53/p21 pathway is functional.
    Lossaint G; Besnard E; Fisher D; Piette J; Dulić V
    Oncogene; 2011 Oct; 30(41):4261-74. PubMed ID: 21532626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IGF-1R inhibition sensitizes breast cancer cells to ATM-related kinase (ATR) inhibitor and cisplatin.
    O'Flanagan CH; O'Shea S; Lyons A; Fogarty FM; McCabe N; Kennedy RD; O'Connor R
    Oncotarget; 2016 Aug; 7(35):56826-56841. PubMed ID: 27472395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.